Vizsgálati helyszín
Hospital Universitari de Santa Maria
Lleida, Lleida [Lérida] 25198, SpanyolországMég nincs intézményhez kötve
- 18futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis16 vizsgálat
- 2. fázis6 vizsgálat
- 4. fázis2 vizsgálat
- Állapot
- Toboroz10 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Lezárult3 vizsgálat
- Még nem toboroz3 vizsgálat
- Leállították2 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Biogen3 vizsgálat
- Bristol-Myers Squibb2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre2 vizsgálat
- LETI Pharma S.L.U.2 vizsgálat
- és még 12
Futó vizsgálatok
Még nem toboroz
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER‑OSA 1)
2026-526327-22-00· 3. fázis· Pfizer Inc.· Forrás
Toboroz
A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease
2025-524314-29-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Még nem toboroz
ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
2026-525500-10-00· 4. fázis· Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre· Forrás
Toboroz
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES)
2025-521709-42-00· 3. fázis· LETI Pharma S.L.U.· Forrás
Toboroz
Grass Immunotherapy for Rhinitis and Asthma (GIRA)
2025-521736-10-00· 3. fázis· LETI Pharma S.L.U.· Forrás
Toboroz
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571005· 3. fázis· Novo Nordisk A/S· Forrás
Még nem toboroz
TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)
2025-524819-37-00· 4. fázis· Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre· Forrás
Toboroz
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011· 3. fázis· Eli Lilly and Company· Forrás
Contact: Ferran Barbé Illa (principal investigator)
Toboroz
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· 3. fázis· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás
Toboroz
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150· 2. fázis· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886· 2. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888· 2. fázis· Biogen· Forrás
Toboroz
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
NCT04891237· 3. fázis· Inmunotek S.L.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Leállították
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· 3. fázis· Biogen· Forrás
Lezárult
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976· 2. fázis· Inmune Bio, Inc.· Forrás
Lezárult
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
2022-501188-42-00· 2. fázis· Janssen - Cilag International· Forrás
Leállították
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· 3. fázis· Biogen· Forrás
Lezárult
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT03393520· 3. fázis· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás
Hibát jelzek